Topics

Human medicines European public assessment report (EPAR): Caelyx, doxorubicin, Sarcoma, Kaposi,Multiple Myeloma,Ovarian Neoplasms,Breast Neoplasms, Date of authorisation: 20/06/1996, Revision: 30, Status: Authorised

08:17 EDT 11 Oct 2019 | European Medicines Agency

Human medicines European public assessment report (EPAR): Caelyx, doxorubicin, Sarcoma, Kaposi,Multiple Myeloma,Ovarian Neoplasms,Breast Neoplasms, Date of authorisation: 20/06/1996, Revision: 30, Status: Authorised

Original Article: Human medicines European public assessment report (EPAR): Caelyx, doxorubicin, Sarcoma, Kaposi,Multiple Myeloma,Ovarian Neoplasms,Breast Neoplasms, Date of authorisation: 20/06/1996, Revision: 30, Status: Authorised

NEXT ARTICLE

More From BioPortfolio on "Human medicines European public assessment report (EPAR): Caelyx, doxorubicin, Sarcoma, Kaposi,Multiple Myeloma,Ovarian Neoplasms,Breast Neoplasms, Date of authorisation: 20/06/1996, Revision: 30, Status: Authorised"

Quick Search

Relevant Topic

Breast Cancer
Track and monitor developments in breast cancer research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...